Yuri Agrawal
Otology & Neurotology Aurora, CO Medical Doctor
NPI 1588710446 CMS profile 1006171
1635 Aurora Ct, Aurora, CO 80045
General payments
$7,397
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Yuri Agrawal of Aurora, CO is reported in the CMS Open Payments database as having received $7,397 across 29 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 76th percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,980 | 6 | |
| 2024 | General | $790 | 7 | |
| 2023 | General | $50 | 1 | |
| 2019 | General | $1,576 | 15 |
Beside peers
- Yuri Agrawal
- Otology & Neurotology median
- Middle half of Otology & Neurotology
- National median
In program year 2025, general payments to Yuri Agrawal were reported at $4,980. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.
Show as a table
| Year | Yuri Agrawal | Otology & Neurotology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,576 | $349 | $117–$1,358 | $163 |
| 2020 | $0 | $118 | $58–$325 | $114 |
| 2021 | $0 | $186 | $81–$600 | $132 |
| 2022 | $0 | $290 | $129–$938 | $149 |
| 2023 | $50 | $335 | $119–$978 | $160 |
| 2024 | $790 | $399 | $138–$1,384 | $164 |
| 2025 | $4,980 | $411 | $148–$1,608 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$11,900
Medicare patients
87
Services billed
167
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 59% | |
| Arthritis | 52% | |
| Ischemic heart disease | 25% | |
| Depression | 24% | |
| Chronic kidney disease | 20% | |
| Diabetes | 17% | |
| Osteoporosis | 16% | |
| Atrial fibrillation | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Otology & Neurotology in Colorado
David Kelsall
Otology & Neurotology · Englewood, CO
James Lupo
Otology & Neurotology · Englewood, CO
Samuel Gubbels
Otology & Neurotology · Aurora, CO
Cameron Shaw
Otology & Neurotology · Colorado Springs, CO
Carol Foster
Otology & Neurotology · Aurora, CO
Alan Lipkin
Otology & Neurotology · Castle Rock, CO
Related records
Otology & Neurotology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Otology & Neurotology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.